A new triazene ligand was prepared by the reaction of the bulky aryl azide, TerMesN, (2,6-bis(2,4,6-trimethylphenyl)phenyl azide), with the bulky N-heterocyclic carbene (NHC), SIPr (,'-2,6-bis(diisopropylphenyl)-3,4-dihydroimidazol-2-ylidene). The steric bulk of these two groups leads to perpendicular bonding of the NHC-N plane and the aryl group which provides immense steric crowding around the triazene core. The corresponding π-conjugated triazene ligand was utilized as a neutral, monodentate ligand which results in monomeric Cu(I)Cl, Ag(I)OTf, and Au(I)Cl complexes. Instability of the π-conjugated triazene Au(I)Cl complex was observed, even under inert conditions. When dissolved and photolyzed in THF with workup in isopropanol, the compound decomposes forming [(SIPrNH)Au(I)][Au(I)Cl] a relatively stable compound to light, moisture, and water - alongside the formation of gold nanoparticles which were characterized using scanning electron microscopy with energy dispersive spectroscopy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d4dt01561d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and Metabolism.
Biochemistry (Mosc)
October 2024
Lomonosov Moscow State University, Moscow, 119991, Russia.
Article Synopsis
- Glutamine is crucial for tumor growth, and its deprivation in solid tumors can hinder their growth and spread, particularly in human glioblastoma cell lines U87MG and T98G.
- Research indicates that U87MG cells, which have a more differentiated phenotype, show increased glycolysis and stemness marker expression (CD133) when deprived of glutamine, while T98G cells shift towards oxidative phosphorylation and become less responsive to certain drugs.
- The study highlights that metabolic and phenotypic differences between these glioblastoma cell lines lead to varying drug sensitivities, suggesting that treatment strategies should consider these differences for better outcomes.
Group 11 complexes of a bulky triazene ligand.
Dalton Trans
August 2024
Department of Chemistry, Saint Mary's University, Halifax, Nova Scotia, Canada B3H 3C3.
A new triazene ligand was prepared by the reaction of the bulky aryl azide, TerMesN, (2,6-bis(2,4,6-trimethylphenyl)phenyl azide), with the bulky N-heterocyclic carbene (NHC), SIPr (,'-2,6-bis(diisopropylphenyl)-3,4-dihydroimidazol-2-ylidene). The steric bulk of these two groups leads to perpendicular bonding of the NHC-N plane and the aryl group which provides immense steric crowding around the triazene core. The corresponding π-conjugated triazene ligand was utilized as a neutral, monodentate ligand which results in monomeric Cu(I)Cl, Ag(I)OTf, and Au(I)Cl complexes.
View Article and Find Full Text PDFEffect of Diminazene Aceturate, an ACE2 activator, on platelet CD40L signaling induced glial activation in rat model of hypertension.
Int Immunopharmacol
September 2024
Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Hypertension causes platelet activation and adhesion in the brain resulting in glial activation and neuroinflammation. Further, activation of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor (ACE2/Ang (1-7)/MasR) axis of central Renin-Angiotensin System (RAS), is known to reduce glial activation and neuroinflammation, thereby exhibiting anti-hypertensive and anti-neuroinflammatory properties. Therefore, in the present study, the role of ACE2/Ang (1-7)/MasR axis was studied on platelet-induced glial activation and neuroinflammation using Diminazene Aceturate (DIZE), an ACE2 activator, in astrocytes and microglial cells as well as in rat model of hypertension.
View Article and Find Full Text PDFDual-targeting liposomes modified with BTP-7 and pHA for combined delivery of TCPP and TMZ to enhance the anti-tumour effect in glioblastoma cells.
J Microencapsul
September 2024
Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Aim: To construct a novel nano-carrier with dual ligands to achieve superior anti-tumour efficacy and lower toxic side effects.
Methods: Liposomes were prepared by thin film hydration method. Ultraviolet, high performance liquid chromatography, nano-size analyser, ultrafiltration centrifugation, dialysis, transmission electron microscope, flow cytometry, Cell Counting Kit-8, confocal laser scanning microscopy, transwell, and tumorsphere assay were used to study the characterisations, cytotoxicity, and targeting of dg-Bcan targeting peptide (BTP-7)/pHA-temozolomide (TMZ)/tetra(4-carboxyphenyl)porphyrin (TCPP)-Lip.
Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
J Nanobiotechnology
May 2024
Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Glioblastoma (GBM) is the most aggressive primary brain tumor with low survival rate. Currently, temozolomide (TMZ) is the first-line drug for GBM treatment of which efficacy is unfortunately hindered by short circulation time and drug resistance associated to hypoxia and redox tumor microenvironment. Herein, a dual-targeted and multi-responsive nanoplatform is developed by loading TMZ in hollow manganese dioxide nanoparticles functionalized by polydopamine and targeting ligands RAP12 for photothermal and receptor-mediated dual-targeted delivery, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!